These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10994885)

  • 1. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report.
    Tzeng AC; Cheng J; Fryczynski H; Niranjan V; Stitik T; Sial A; Takeuchi Y; Foye P; DePrince M; Bach JR
    Am J Phys Med Rehabil; 2000; 79(5):435-40. PubMed ID: 10994885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of thyrotropin-releasing hormone in the treatment of spinal muscular atrophy.
    Takeuchi Y; Miyanomae Y; Komatsu H; Oomizono Y; Nishimura A; Okano S; Nishiki T; Sawada T
    J Child Neurol; 1994 Jul; 9(3):287-9. PubMed ID: 7930408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy.
    Kato Z; Okuda M; Okumura Y; Arai T; Teramoto T; Nishimura M; Kaneko H; Kondo N
    J Child Neurol; 2009 Aug; 24(8):1010-2. PubMed ID: 19666885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: evidence of activity-dependent conduction block.
    Noto Y; Misawa S; Mori M; Kawaguchi N; Kanai K; Shibuya K; Isose S; Nasu S; Sekiguchi Y; Beppu M; Ohmori S; Nakagawa M; Kuwabara S
    Clin Neurophysiol; 2013 Sep; 124(9):1893-8. PubMed ID: 23643309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy.
    Chen TH; Chang JG; Yang YH; Mai HH; Liang WC; Wu YC; Wang HY; Huang YB; Wu SM; Chen YC; Yang SN; Jong YJ
    Neurology; 2010 Dec; 75(24):2190-7. PubMed ID: 21172842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries.
    Pitts LH; Ross A; Chase GA; Faden AI
    J Neurotrauma; 1995 Jun; 12(3):235-43. PubMed ID: 7473798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
    Kirschner J; Schorling D; Hauschke D; Rensing-Zimmermann C; Wein U; Grieben U; Schottmann G; Schara U; Konrad K; Müller-Felber W; Thiele S; Wilichowski E; Hobbiebrunken E; Stettner GM; Korinthenberg R
    Neuromuscul Disord; 2014 Feb; 24(2):134-42. PubMed ID: 24300782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotropin-releasing hormone (TRH) in murine motor neuron disease (the wobbler mouse).
    Kozachuk WE; Mitsumoto H; Salanga VD; Beck GJ; Wilber JF
    J Neurol Sci; 1987 May; 78(3):253-60. PubMed ID: 3108458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of muscle strength with a handheld dynamometer in patients with chronic spinal muscular atrophy.
    Febrer A; Rodriguez N; Alias L; Tizzano E
    J Rehabil Med; 2010 Mar; 42(3):228-31. PubMed ID: 20411217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.
    Mitsumoto H; Salgado ED; Negroski D; Hanson MR; Salanga VD; Wilber JF; Wilbourn AJ; Breuer AC; Leatherman J
    Neurology; 1986 Feb; 36(2):152-9. PubMed ID: 3080695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid treatment in six patients with spinal muscular atrophy.
    Tsai LK; Yang CC; Hwu WL; Li H
    Eur J Neurol; 2007 Dec; 14(12):e8-9. PubMed ID: 18028187
    [No Abstract]   [Full Text] [Related]  

  • 13. Beneficial effect of thyrotropin-releasing hormone on neuropathy in diabetic rats.
    Gul H; Odabasi Z; Yildiz O; Ozata M; Deniz G; Vural O; Isimer A
    Diabetes Res Clin Pract; 1999 May; 44(2):93-100. PubMed ID: 10414927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autosomal dominant congenital spinal muscular atrophy: a true form of spinal muscular atrophy caused by early loss of anterior horn cells.
    Oates EC; Reddel S; Rodriguez ML; Gandolfo LC; Bahlo M; Hawke SH; Lamandé SR; Clarke NF; North KN
    Brain; 2012 Jun; 135(Pt 6):1714-23. PubMed ID: 22628388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of thyrotropin releasing hormone (TRH) therapy on regional cerebral blood flow in the cerebellar variant of multiple system atrophy using 3DSRT.
    Kimura N; Kumamoto T; Masuda T; Nomura Y; Hanaoka T; Hazama Y; Okazaki T
    J Neuroimaging; 2011 Apr; 21(2):132-7. PubMed ID: 19674246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between the M and F wave characteristics and the innervated muscle strength in spinal muscular atrophy.
    Imai T; Saito M; Matsumoto H; Ishikawa Y; Ishikawa Y; Minami R
    Brain Dev; 1998 Jan; 20(1):44-6. PubMed ID: 9533560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
    Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy.
    Mercuri E; Bertini E; Messina S; Solari A; D'Amico A; Angelozzi C; Battini R; Berardinelli A; Boffi P; Bruno C; Cini C; Colitto F; Kinali M; Minetti C; Mongini T; Morandi L; Neri G; Orcesi S; Pane M; Pelliccioni M; Pini A; Tiziano FD; Villanova M; Vita G; Brahe C
    Neurology; 2007 Jan; 68(1):51-5. PubMed ID: 17082463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients.
    Marangell LB; George MS; Callahan AM; Ketter TA; Pazzaglia PJ; L'Herrou TA; Leverich GS; Post RM
    Arch Gen Psychiatry; 1997 Mar; 54(3):214-22. PubMed ID: 9075462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.